Diverse mechanisms of AKT pathway activation in human malignancy

Current Cancer Drug Targets

Volumn 13, Issue 3, 2013, Pages 234-244

  Cheung, Mitchell ^a   Testa, Joseph R ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

AKT PKB kinases; Hemimegalencephaly; Human malignancy; Hypoglycemia; Oncogenes; Proteus syndrome; Targeted therapies; Tumor suppressor genes

Indexed keywords

1 [4 [1 (1, 4 DIOXASPIRO [4.5] DEC 8 YL) 4 (8 OXA 3 AZABICYCLO [3.2.1] OCT 3 YL) 1H PYRAZOLO [3, 4 D] PYRIMIDIN 6 YL] PHENYL] 3 METHYLUREA; 1 [4 [1 (1,4 DIOXASPIRO[4.5]DEC 8 YL) 4 (8 OXA 3 AZABICYCLO[3.2.1]OCT 3 YL) 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]PHENYL] 3 METHYLUREA; AXITINIB; BEVACIZUMAB; CYCLIN D1; EVEROLIMUS; HEAT SHOCK PROTEIN 90; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE B BETA; PROTEIN KINASE LKB1; PROTEIN P53; PROTEIN TYROSINE KINASE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TUBERIN; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

CANCER PROGNOSIS; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFICACY; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; HUMAN; INSULIN RELEASE; KIDNEY CANCER; KIDNEY CARCINOMA; NEOPLASM; NEUROFIBROMATOSIS; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; HUMANS; MICE; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84876852762     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009611313030002     Document Type: Review

References (103)

1. Bellacosa, A.; Kumar, C. C.; Di Cristofano, A.; Testa, J. R. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv. Cancer Res. 2005, 94, 29-86.
2. Scheid, M. P.; Woodgett, J. R. Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett. 2003, 546 (1), 108-112.
3. Cheon, D. J.; Orsulic, S. Mouse Models of Cancer. Annu. Rev. Pathol. 2010, 6, 95-119.
4. Singh, M.; Johnson, L. Using genetically engineered mouse models of cancer to aid drug development: an industry perspective. Clin. Cancer Res. 2006, 12 (18), 5312-5328.
5. Brems, H.; Beert, E.; de Ravel, T.; Legius, E. Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol. 2009, 10 (5), 508-515.
6. Tucker, M.; Goldstein, A.; Dean, M.; Knudson, A. National Cancer Institute Workshop Report: the phakomatoses revisited. J. Natl. Cancer Inst. 2000, 92 (7), 530-533.
7. Hobert, J. A.; Eng, C. PTEN hamartoma tumor syndrome: an overview. Genet. Med. 2009, 11 (10), 687-694.
8. Downward, J. PI 3-kinase, Akt and cell survival. Semin. Cell Dev. Biol. 2004, 15 (2), 177-182.
9. Pommier, Y.; Sordet, O.; Antony, S.; Hayward, R. L.; Kohn, K. W. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004, 23 (16), 2934-2949.
10. Zhou, B. P.; Liao, Y.; Xia, W.; Zou, Y.; Spohn, B.; Hung, M. C. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol. 2001, 3 (11), 973-982.
11. Mayo, L. D.; Donner, D. B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. USA 2001, 98 (20), 11598-11603.
12. Park, S.; Kim, D.; Dan, H. C.; Chen, H.; Testa, J. R.; Cheng, J. Q. Identification of an Akt interaction protein, PHF20/TZP, that transcriptionally regulates p53. J. Biol. Chem. 2012, 287 (14), 11151-11163.
13. Testa, J. R.; Bellacosa, A. AKT plays a central role in tumorigenesis. Proc. Natl. Acad. Sci. USA 2001, 98 (20), 10983-10985.
14. Ciuffreda, L.; Di Sanza, C.; Incani, U. C.; Milella, M. The mTOR pathway: a new target in cancer therapy. Curr. Cancer Drug Targets 2010, 10 (5), 484-495.
15. Ruggero, D.; Sonenberg, N. The Akt of translational control. Oncogene 2005, 24 (50), 7426-7434.
16. Plas, D. R.; Thompson, C. B. Akt-dependent transformation: there is more to growth than just surviving. Oncogene 2005, 24 (50), 7435-7442.
17. Ruggero, D.; Pandolfi, P. P. Does the ribosome translate cancer? Nat. Rev. Cancer 2003, 3 (3), 179-192.
18. Bjornsti, M. A.; Houghton, P. J. Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell 2004, 5 (6), 519-523.
19. Jiang, B. H.; Liu, L. Z. AKT signaling in regulating angiogenesis. Curr. Cancer Drug Targets 2008, 8 (1), 19-26.
20. Toschi, A.; Lee, E.; Gadir, N.; Ohh, M.; Foster, D. A. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J. Biol. Chem. 2008, 283 (50), 34495-34499.
21. Bian, C. X.; Shi, Z.; Meng, Q.; Jiang, Y.; Liu, L. Z.; Jiang, B. H. P70S6K 1 regulation of angiogenesis through VEGF and HIF-1alpha expression. Biochem. Biophys. Res. Commun. 2010, 398 (3), 395-399.
22. Liu, L. Z.; Zheng, J. Z.; Wang, X. R.; Jiang, B. H. Endothelial p70 S6 kinase 1 in regulating tumor angiogenesis. Cancer Res. 2008, 68 (19), 8183-8188.
23. Yeung, S. J.; Pan, J.; Lee, M. H. Roles of p53, MYC and HIF-1 in regulating glycolysis-the seventh hallmark of cancer. Cell Mol. Life Sci. 2008, 65 (24), 3981-3999.
24. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100 (1), 57-70.
25. Shiojima, I.; Walsh, K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ. Res. 2002, 90 (12), 1243-1250.
26. Thant, A. A.; Nawa, A.; Kikkawa, F.; Ichigotani, Y.; Zhang, Y.; Sein, T. T.; Amin, A. R.; Hamaguchi, M. Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells. Clin. Exp. Metastasis 2000, 18 (5), 423-428.
27. Larue, L.; Bellacosa, A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene 2005, 24 (50), 7443-7454.
28. Liu, J. P. Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J. 1999, 13 (15), 2091-2104.
29. Cheng, J. Q.; Godwin, A. K.; Bellacosa, A.; Taguchi, T.; Franke, T. F.; Hamilton, T. C.; Tsichlis, P. N.; Testa, J. R. AKT2, a putative oncogene encoding a member of a subfamily of proteinserine/ threonine kinases, is amplified in human ovarian carcinomas. Proc. Natl. Acad. Sci. USA 1992, 89 (19), 9267-9271.
30. Bellacosa, A.; de Feo, D.; Godwin, A. K.; Bell, D. W.; Cheng, J. Q.; Altomare, D. A.; Wan, M.; Dubeau, L.; Scambia, G.; Masciullo, V.; Ferrandina, G.; Benedetti Panici, P.; Mancuso, S.; Neri, G.; Testa, J. R. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 1995, 64 (4), 280-285.
31. Nakayama, K.; Nakayama, N.; Jinawath, N.; Salani, R.; Kurman, R. J.; Shih Ie, M.; Wang, T. L. Amplicon profiles in ovarian serous carcinomas. Int. J. Cancer 2007, 120 (12), 2613-2617.
32. Noske, A.; Kaszubiak, A.; Weichert, W.; Sers, C.; Niesporek, S.; Koch, I.; Schaefer, B.; Sehouli, J.; Dietel, M.; Lage, H.; Denkert, C. Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer. Cancer Lett. 2007, 246 (1-2), 190-200.
33. Xing, H.; Weng, D.; Chen, G.; Tao, W.; Zhu, T.; Yang, X.; Meng, L.; Wang, S.; Lu, Y.; Ma, D. Activation of fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells. Cancer Lett. 2008, 261 (1), 108-119.
34. Weng, D.; Song, X.; Xing, H.; Ma, X.; Xia, X.; Weng, Y.; Zhou, J.; Xu, G.; Meng, L.; Zhu, T.; Wang, S.; Ma, D. Implication of the Akt2/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells. Cancer Lett. 2009, 273 (2), 257-265.
35. Arboleda, M. J.; Lyons, J. F.; Kabbinavar, F. F.; Bray, M. R.; Snow, B. E.; Ayala, R.; Danino, M.; Karlan, B. Y.; Slamon, D. J. Overexpression of AKT2/protein kinase Bbeta leads to upregulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res. 2003, 63 (1), 196-206.
36. Cheng, J. Q.; Ruggeri, B.; Klein, W. M.; Sonoda, G.; Altomare, D. A.; Watson, D. K.; Testa, J. R. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl. Acad. Sci. USA 1996, 93 (8), 3636-3641.
37. Miwa, W.; Yasuda, J.; Murakami, Y.; Yashima, K.; Sugano, K.; Sekine, T.; Kono, A.; Egawa, S.; Yamaguchi, K.; Hayashizaki, Y.; Sekiya, T. Isolation of DNA sequences amplified at chromosome 19q13.1-q13.2 including the AKT2 locus in human pancreatic cancer. Biochem. Biophys. Res. Commun. 1996, 225 (3), 968-974.
38. Ruggeri, B. A.; Huang, L.; Wood, M.; Cheng, J. Q.; Testa, J. R. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol. Carcinog. 1998, 21 (2), 81-86.
39. Altomare, D. A.; Tanno, S.; De Rienzo, A.; Klein-Szanto, A. J.; Skele, K. L.; Hoffman, J. P.; Testa, J. R. Frequent activation of AKT2 kinase in human pancreatic carcinomas. J. Cell. Biochem. 2002, 87 (4), 470-476.
40. Hashimoto, K.; Mori, N.; Tamesa, T.; Okada, T.; Kawauchi, S.; Oga, A.; Furuya, T.; Tangoku, A.; Oka, M.; Sasaki, K. Analysis of DNA copy number aberrations in hepatitis C virus-associated hepatocellular carcinomas by conventional CGH and array CGH. Mod. Pathol. 2004, 17 (6), 617-622.
41. Ichimura, K.; Vogazianou, A. P.; Liu, L.; Pearson, D. M.; Backlund, L. M.; Plant, K.; Baird, K.; Langford, C. F.; Gregory, S. G.; Collins, V. P. 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. Oncogene 2008, 27 (14), 2097-2108.
42. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455 (7216), 1061-1068.
43. Stahl, J. M.; Sharma, A.; Cheung, M.; Zimmerman, M.; Cheng, J. Q.; Bosenberg, M. W.; Kester, M.; Sandirasegarane, L.; Robertson, G. P. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 2004, 64 (19), 7002-7010.
44. Cristiano, B. E.; Chan, J. C.; Hannan, K. M.; Lundie, N. A.; Marmy-Conus, N. J.; Campbell, I. G.; Phillips, W. A.; Robbie, M.; Hannan, R. D.; Pearson, R. B. A specific role for AKT3 in the genesis of ovarian cancer through modulation of G(2)-M phase transition. Cancer Res. 2006, 66 (24), 11718-11725.
45. Carpten, J. D.; Faber, A. L.; Horn, C.; Donoho, G. P.; Briggs, S. L.; Robbins, C. M.; Hostetter, G.; Boguslawski, S.; Moses, T. Y.; Savage, S.; Uhlik, M.; Lin, A.; Du, J.; Qian, Y. W.; Zeckner, D. J.; Tucker-Kellogg, G.; Touchman, J.; Patel, K.; Mousses, S.; Bittner, M.; Schevitz, R.; Lai, M. H.; Blanchard, K. L.; Thomas, J. E. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007, 448 (7152), 439-444.
46. Bleeker, F. E.; Felicioni, L.; Buttitta, F.; Lamba, S.; Cardone, L.; Rodolfo, M.; Scarpa, A.; Leenstra, S.; Frattini, M.; Barbareschi, M.; Grammastro, M. D.; Sciarrotta, M. G.; Zanon, C.; Marchetti, A.; Bardelli, A. AKT1(E17K) in human solid tumours. Oncogene 2008, 27 (42), 5648-5650.
47. Davies, M. A.; Stemke-Hale, K.; Tellez, C.; Calderone, T. L.; Deng, W.; Prieto, V. G.; Lazar, A. J.; Gershenwald, J. E.; Mills, G. B. A novel AKT3 mutation in melanoma tumours and cell lines. Br. J. Cancer 2008, 99 (8), 1265-1268.
48. Shoji, K.; Oda, K.; Nakagawa, S.; Hosokawa, S.; Nagae, G.; Uehara, Y.; Sone, K.; Miyamoto, Y.; Hiraike, H.; Hiraike-Wada, O.; Nei, T.; Kawana, K.; Kuramoto, H.; Aburatani, H.; Yano, T.; Taketani, Y. The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br. J. Cancer 2009, 101 (1), 145-148.
49. Cohen, Y.; Shalmon, B.; Korach, J.; Barshack, I.; Fridman, E.; Rechavi, G. AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma. Gynecol. Oncol. 2010, 116 (1), 88-91.
50. Askham, J. M.; Platt, F.; Chambers, P. A.; Snowden, H.; Taylor, C. F.; Knowles, M. A. AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K. Oncogene 2010, 29 (1), 150-155.
51. Boormans, J. L.; Korsten, H.; Ziel-van der Made, A. C.; van Leenders, G. J.; Verhagen, P. C.; Trapman, J. E17K substitution in AKT1 in prostate cancer. Br. J. Cancer 2010, 102 (10), 1491-1494.
52. Lemmon, M. A.; Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141 (7), 1117-1134.
53. Steeghs, N.; Nortier, J. W.; Gelderblom, H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann. Surg. Oncol. 2007, 14 (2), 942-953.
54. Shayesteh, L.; Lu, Y.; Kuo, W. L.; Baldocchi, R.; Godfrey, T.; Collins, C.; Pinkel, D.; Powell, B.; Mills, G. B.; Gray, J. W. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. 1999, 21 (1), 99-102.
55. Pedrero, J. M.; Carracedo, D. G.; Pinto, C. M.; Zapatero, A. H.; Rodrigo, J. P.; Nieto, C. S.; Gonzalez, M. V. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int. J. Cancer 2005, 114 (2), 242-248.
56. Byun, D. S.; Cho, K.; Ryu, B. K.; Lee, M. G.; Park, J. I.; Chae, K. S.; Kim, H. J.; Chi, S. G. Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma. Int. J. Cancer 2003, 104 (3), 318-327.
57. Salvesen, H. B.; Carter, S. L.; Mannelqvist, M.; Dutt, A.; Getz, G.; Stefansson, I. M.; Raeder, M. B.; Sos, M. L.; Engelsen, I. B.; Trovik, J.; Wik, E.; Greulich, H.; Bo, T. H.; Jonassen, I.; Thomas, R. K.; Zander, T.; Garraway, L. A.; Oyan, A. M.; Sellers, W. R.; Kalland, K. H.; Meyerson, M.; Akslen, L. A.; Beroukhim, R. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc. Natl. Acad. Sci. USA 2009, 106 (12), 4834-4839.
58. Shi, J.; Yao, D.; Liu, W.; Wang, N.; Lv, H.; Zhang, G.; Ji, M.; Xu, L.; He, N.; Shi, B.; Hou, P. Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer. BMC Cancer 2012, 12, 50.
59. Kang, S.; Bader, A. G.; Vogt, P. K. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl. Acad. Sci. USA 2005, 102 (3), 802-807.
60. Kuo, K. T.; Mao, T. L.; Jones, S.; Veras, E.; Ayhan, A.; Wang, T. L.; Glas, R.; Slamon, D.; Velculescu, V. E.; Kuman, R. J.; Shih Ie, M. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am. J. Pathol. 2009, 174 (5), 1597-1601.
61. O'Brien, C.; Wallin, J. J.; Sampath, D.; GuhaThakurta, D.; Savage, H.; Punnoose, E. A.; Guan, J.; Berry, L.; Prior, W. W.; Amler, L. C.; Belvin, M.; Friedman, L. S.; Lackner, M. R. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin. Cancer Res. 2010, 16 (14), 3670-3683.
62. Philp, A. J.; Campbell, I. G.; Leet, C.; Vincan, E.; Rockman, S. P.; Whitehead, R. H.; Thomas, R. J.; Phillips, W. A. The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res. 2001, 61 (20), 7426-7429.
63. Taniguchi, C. M.; Winnay, J.; Kondo, T.; Bronson, R. T.; Guimaraes, A. R.; Aleman, J. O.; Luo, J.; Stephanopoulos, G.; Weissleder, R.; Cantley, L. C.; Kahn, C. R. The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling. Cancer Res. 2010, 70 (13), 5305-5315.
64. Chalhoub, N.; Baker, S. J. PTEN and the PI3-kinase pathway in cancer. Annu. Rev. Pathol. 2009, 4, 127-150.
65. Couto, S. S.; Cao, M.; Duarte, P. C.; Banach-Petrosky, W.; Wang, S.; Romanienko, P.; Wu, H.; Cardiff, R. D.; Abate-Shen, C.; Cunha, G. R. Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer. Differentiation 2009, 77 (1), 103-111.
66. Basso, A. D.; Solit, D. B.; Chiosis, G.; Giri, B.; Tsichlis, P.; Rosen, N. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J. Biol. Chem. 2002, 277 (42), 39858-39866.
67. Porter, J. R.; Fritz, C. C.; Depew, K. M. Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr. Opin. Chem. Biol. 2010, 14 (3), 412-420.
68. Liu, J.; Weiss, H. L.; Rychahou, P.; Jackson, L. N.; Evers, B. M.; Gao, T. Loss of PHLPP expression in colon cancer: role in proliferation and tumorigenesis. Oncogene 2009, 28 (7), 994-1004.
69. Ouillette, P.; Erba, H.; Kujawski, L.; Kaminski, M.; Shedden, K.; Malek, S. N. Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. Cancer Res. 2008, 68 (4), 1012-1021.
70. Chen, M.; Pratt, C. P.; Zeeman, M. E.; Schultz, N.; Taylor, B. S.; O'Neill, A.; Castillo-Martin, M.; Nowak, D. G.; Naguib, A.; Grace, D. M.; Murn, J.; Navin, N.; Atwal, G. S.; Sander, C.; Gerald, W. L.; Cordon-Cardo, C.; Newton, A. C.; Carver, B. S.; Trotman, L. C. Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. Cancer Cell 2011, 20 (2), 173-186.
71. Molina, J. R.; Agarwal, N. K.; Morales, F. C.; Hayashi, Y.; Aldape, K. D.; Cote, G.; Georgescu, M. M. PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma. Oncogene 2012, 31 (10), 1264-1274.
72. Lovat, F.; Valeri, N.; Croce, C. M. MicroRNAs in the pathogenesis of cancer. Semin. Oncol. 2011, 38 (6), 724-733.
73. Liu, L. Z.; Li, C.; Chen, Q.; Jing, Y.; Carpenter, R.; Jiang, Y.; Kung, H. F.; Lai, L.; Jiang, B. H. MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1alpha expression. PLoS One 2011, 6 (4), e19139.
74. Lou, Y.; Yang, X.; Wang, F.; Cui, Z.; Huang, Y. MicroRNA-21 promotes the cell proliferation, invasion and migration abilities in ovarian epithelial carcinomas through inhibiting the expression of PTEN protein. Int. J. Mol. Med. 2010, 26 (6), 819-827.
75. Xu, Q.; Liu, L. Z.; Qian, X.; Chen, Q.; Jiang, Y.; Li, D.; Lai, L.; Jiang, B. H. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res. 2012, 40 (2), 761-774.
76. Shi, Z. M.; Wang, J.; Yan, Z.; You, Y. P.; Li, C. Y.; Qian, X.; Yin, Y.; Zhao, P.; Wang, Y. Y.; Wang, X. F.; Li, M. N.; Liu, L. Z.; Liu, N.; Jiang, B. H. MiR-128 Inhibits Tumor Growth and Angiogenesis by Targeting p70S6K1. PLoS One 2012, 7 (3), e32709.
77. Zhou, L.; Zhao, Y. P.; Liu, W. J.; Dong, J.; Chen, W. Y.; Zhang, T. P.; Chen, G.; Shu, H. Circulating microRNAs in cancer: diagnostic and prognostic significance. Expert Rev. Anticancer Ther. 2012, 12 (2), 283-288.
78. Eng, C. PTEN: one gene, many syndromes. Hum. Mutat. 2003, 22 (3), 183-198.
79. Teresi, R. E.; Zbuk, K. M.; Pezzolesi, M. G.; Waite, K. A.; Eng, C. Cowden syndrome-affected patients with PTEN promoter mutations demonstrate abnormal protein translation. Am. J. Hum. Genet. 2007, 81 (4), 756-767.
80. Astrinidis, A.; Henske, E. P. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene 2005, 24 (50), 7475-7481.
81. Pymar, L. S.; Platt, F. M.; Askham, J. M.; Morrison, E. E.; Knowles, M. A. Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms. Hum. Mol. Genet. 2008, 17 (13), 2006-2017.
82. Sampson, J. R. Therapeutic targeting of mTOR in tuberous sclerosis. Biochem. Soc. Trans. 2009, 37 (Pt 1), 259-264.
83. Sanchez-Cespedes, M. A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome. Oncogene 2007, 26 (57), 7825-7832.
84. Wei, C.; Amos, C. I.; Zhang, N.; Wang, X.; Rashid, A.; Walker, C. L.; Behringer, R. R.; Frazier, M. L. Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling. Clin. Cancer Res. 2008, 14 (4), 1167-1171.
85. Wei, C.; Amos, C. I.; Zhang, N.; Zhu, J.; Wang, X.; Frazier, M. L. Chemopreventive efficacy of rapamycin on Peutz-Jeghers syndrome in a mouse model. Cancer Lett. 2009, 277 (2), 149-154.
86. Shackelford, D. B.; Vasquez, D. S.; Corbeil, J.; Wu, S.; Leblanc, M.; Wu, C. L.; Vera, D. R.; Shaw, R. J. mTOR and HIF-1alphamediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc. Natl. Acad. Sci. USA 2009, 106 (27), 11137-11142.
87. Johannessen, C. M.; Johnson, B. W.; Williams, S. M.; Chan, A. W.; Reczek, E. E.; Lynch, R. C.; Rioth, M. J.; McClatchey, A.; Ryeom, S.; Cichowski, K. TORC1 is essential for NF1-associated malignancies. Curr. Biol. 2008, 18 (1), 56-62.
88. Nordstrom-O'Brien, M.; van der Luijt, R. B.; van Rooijen, E.; van den Ouweland, A. M.; Majoor-Krakauer, D. F.; Lolkema, M. P.; van Brussel, A.; Voest, E. E.; Giles, R. H. Genetic analysis of von Hippel-Lindau disease. Hum. Mutat. 2010, 31 (5), 521-537.
89. Linehan, W. M.; Bratslavsky, G.; Pinto, P. A.; Schmidt, L. S.; Neckers, L.; Bottaro, D. P.; Srinivasan, R. Molecular diagnosis and therapy of kidney cancer. Annu. Rev. Med. 2010, 61, 329-343.
90. Singer, E. A.; Gupta, G. N.; Srinivasan, R. Targeted therapeutic strategies for the management of renal cell carcinoma. Curr. Opin. Oncol. 2012, 24 (3), 284-290.
91. Yu, K.; Shi, C.; Toral-Barza, L.; Lucas, J.; Shor, B.; Kim, J. E.; Zhang, W. G.; Mahoney, R.; Gaydos, C.; Tardio, L.; Kim, S. K.; Conant, R.; Curran, K.; Kaplan, J.; Verheijen, J.; Ayral-Kaloustian, S.; Mansour, T. S.; Abraham, R. T.; Zask, A.; Gibbons, J. J. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res. 2010, 70 (2), 621-631.
92. Cho, H.; Thorvaldsen, J. L.; Chu, Q.; Feng, F.; Birnbaum, M. J. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem. 2001, 276 (42), 38349-38352.
93. Cho, H.; Mu, J.; Kim, J. K.; Thorvaldsen, J. L.; Chu, Q.; Crenshaw, E. B., 3rd; Kaestner, K. H.; Bartolomei, M. S.; Shulman, G. I.; Birnbaum, M. J. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 2001, 292 (5522), 1728-1731.
94. Altomare, D. A.; Lyons, G. E.; Mitsuuchi, Y.; Cheng, J. Q.; Testa, J. R. Akt2 mRNA is highly expressed in embryonic brown fat and the AKT2 kinase is activated by insulin. Oncogene 1998, 16 (18), 2407-2411.
95. Easton, R. M.; Cho, H.; Roovers, K.; Shineman, D. W.; Mizrahi, M.; Forman, M. S.; Lee, V. M.; Szabolcs, M.; de Jong, R.; Oltersdorf, T.; Ludwig, T.; Efstratiadis, A.; Birnbaum, M. J. Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol. Cell. Biol. 2005, 25 (5), 1869-1878.
96. Lindhurst, M. J.; Sapp, J. C.; Teer, J. K.; Johnston, J. J.; Finn, E. M.; Peters, K.; Turner, J.; Cannons, J. L.; Bick, D.; Blakemore, L.; Blumhorst, C.; Brockmann, K.; Calder, P.; Cherman, N.; Deardorff, M. A.; Everman, D. B.; Golas, G.; Greenstein, R. M.; Kato, B. M.; Keppler-Noreuil, K. M.; Kuznetsov, S. A.; Miyamoto, R. T.; Newman, K.; Ng, D.; O'Brien, K.; Rothenberg, S.; Schwartzentruber, D. J.; Singhal, V.; Tirabosco, R.; Upton, J.; Wientroub, S.; Zackai, E. H.; Hoag, K.; Whitewood-Neal, T.; Robey, P. G.; Schwartzberg, P. L.; Darling, T. N.; Tosi, L. L.; Mullikin, J. C.; Biesecker, L. G. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N. Engl. J. Med. 2011, 365 (7), 611-619.
97. Cohen, M. M. Jr. Proteus syndrome: an update. Am. J. Med. Genet. C. Semin. Med. Genet. 2005, 137C (1), 38-52.
98. Marsh, D. J.; Trahair, T. N.; Kirk, E. P. Mutant AKT1 in Proteus syndrome. N. Engl. J. Med. 2011, 365 (22), 2141-2142; author reply 2142.
99. Marsh, D. J.; Trahair, T. N.; Martin, J. L.; Chee, W. Y.; Walker, J.; Kirk, E. P.; Baxter, R. C.; Marshall, G. M. Rapamycin treatment for a child with germline PTEN mutation. Nat. Clin. Pract. Oncol. 2008, 5 (6), 357-361.
100. Cohen, M. M. Jr.; Turner, J. T.; Biesecker, L. G. Proteus syndrome: misdiagnosis with PTEN mutations. Am. J. Med. Genet. A. 2003, 122A (4), 323-324.
101. Hussain, K.; Challis, B.; Rocha, N.; Payne, F.; Minic, M.; Thompson, A.; Daly, A.; Scott, C.; Harris, J.; Smillie, B. J.; Savage, D. B.; Ramaswami, U.; De Lonlay, P.; O'Rahilly, S.; Barroso, I.; Semple, R. K. An activating mutation of AKT2 and human hypoglycemia. Science 2011, 334 (6055), 474.
102. Poduri, A.; Evrony, G. D.; Cai, X.; Elhosary, P. C.; Beroukhim, R.; Lehtinen, M. K.; Hills, L. B.; Heinzen, E. L.; Hill, A.; Hill, R. S.; Barry, B. J.; Bourgeois, B. F. D.; Riviello, J. J.; Barkovich, A. J.; Black, P. M.; Ligon, K. L.; Walsh, C. A. Somatic Activation of AKT3 Causes Hemispheric Developmental Brain Malformations. Neuron. 2012, 74 (1), 41-48.
103. Tokuda, S.; Mahaffey, C. L.; Monks, B.; Faulkner, C. R.; Birnbaum, M. J.; Danzer, S. C.; Frankel, W. N. A novel Akt3 mutation associated with enhanced kinase activity and seizure susceptibility in mice. Hum. Mol. Genet. 2011, 20 (5), 988-999.